This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
by Zacks Equity Research
Roche has collaborated with Zealand Pharma to develop and commercialize petrelintide for obesity
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
by Zacks Equity Research
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More
by Kinjel Shah
Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
by Zacks Equity Research
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
by Zacks Equity Research
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
by Zacks Equity Research
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
by Zacks Equity Research
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
by Zacks Equity Research
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
by Kinjel Shah
NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
by Zacks Equity Research
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
by Zacks Equity Research
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs
by Zacks Equity Research
ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
by Zacks Equity Research
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
by Kinjel Shah
SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
by Zacks Equity Research
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
by Sundeep Ganoria
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
by Zacks Equity Research
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
by Zacks Equity Research
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea HD (on a preliminary basis).
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
by Zacks Equity Research
Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
by Zacks Equity Research
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.